The companies originally partnered in September 2023 in an agreement that allowed for the development of up to 11 drug ...
Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular dis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback